Detalles de la búsqueda
1.
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Int J Gynecol Cancer
; 34(4): 550-558, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38129136
2.
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Lancet
; 399(10336): 1695-1707, 2022 04 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35405085
3.
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.
Gynecol Oncol
; 170: 186-194, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36706645
4.
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study.
Gynecol Oncol
; 165(1): 30-39, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35123771
5.
Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients.
Int J Cancer
; 146(6): 1643-1651, 2020 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31318983
6.
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Lancet
; 393(10191): 2591-2598, 2019 06 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-31178155
7.
Feasibility and efficacy of a supervised home-based physical exercise program for metastatic cancer patients receiving oral targeted therapy: study protocol for the phase II/III - UNICANCER SdS 01 QUALIOR trial.
BMC Cancer
; 20(1): 975, 2020 Oct 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33036567
8.
Non-pegylated liposomal doxorubicin (NPLD, Myocet®)â¯+â¯carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial.
Gynecol Oncol
; 152(1): 68-75, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30446275
9.
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Lancet Oncol
; 14(8): 741-8, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23764181
10.
Geriatric Assessment Implementation before Chemotherapy in MEtastatic Prostate Cancer, Results from the Real-Life Study GAMERS.
J Clin Med
; 12(4)2023 Feb 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36836171
11.
Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group.
Mol Oncol
; 17(1): 27-36, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36370117
12.
Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study.
Lancet Healthy Longev
; 3(3): e176-e185, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36098291
13.
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial.
Ther Adv Med Oncol
; 14: 17588359221126149, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36172173
14.
Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database.
Breast
; 60: 138-146, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34624756
15.
Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial.
Clin Genitourin Cancer
; 19(6): 554-562, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34602349
16.
Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer.
Sci Rep
; 10(1): 10757, 2020 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32612272
17.
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial.
Clin Cancer Res
; 26(17): 4625-4632, 2020 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32209570
18.
Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial.
Clin Cancer Res
; 24(22): 5534-5542, 2018 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30061359
19.
Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.
Ther Adv Med Oncol
; 9(5): 335-346, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28529550
20.
Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study.
Eur J Cancer
; 62: 28-35, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27192659